Skip to content
RSV, Virus RSV, Virus

Risk Factors and Clinical Burden of RSV in Older Adults

While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalisation and death, particularly in older adults and those with underlying conditions1

Risk Factors

Risk factors for severe RSV disease in adults include:

The risk of RSV- associated hospitalisation increases with age.

RSV, Hospitalization

A large prospective study estimated the incidence of RSV-associated hospitalisation in two regions of New York State, USA, 2017–2020. N=1099 cases:2

RSV, Graph, Hospitalization

This graph was independently created for GSK from the original data

Hospitalisation rates for RSV were higher in adults with underlying conditions2

Comorbidity Incidence rate ratio*
50-64y 2.34 3.60
≥65y 2.52 2.27
50-64y 3.36 3.58
≥65y 6.44 2.35
50-64y 3.74 4.41
≥65y 6.46 3.75
60-79y 7.63 5.86
≥80y 3.99 5.40

*Ratio of rate among people with each comorbidity versus those without it, in the surveillance area population

Burden of Disease

RSV can cause severe complications in older adults

In older adults hospitalised with RSV, the risk of severe outcomes is comparable to those hospitalised with influenza

RSV, Complications, Adults, Graph

This graph was independently created for GSK from the original data

Economic Burden of RSV in Older Adults

RSV, Hospital

Learn more about RSV disease and its burden in adults:


CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NYC, New York City; RSV, respiratory syncytial virus


  1. CDC, 2023. RSV in older adults and adults with chronic medical conditions. Accessed September 2023.
  2. Branche AR et al. Clin Infect Dis. 2022 Mar 23;74(6):1004-1011. doi: 10.1093/cid/ciab595.
  3. Belongia EA et al. Open Forum Infect Dis 2018;27;5:ofy316.
  4. Walker E, Ison MG. Influenza Other Respir Viruses 2014;8:282–292.
  5. Ackerson B et al. Clin Infect Dis 2019;69:197–203.
  6. Lee N et al. Clin Infect Dis 2013; 57:1069–1077.
  7. Troeger C et al. Lancet Infect Dis 2018;18:1191-1210.
  8. Falsey AR et al. N Engl J Med 2005;352:1749–1759.

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

©2023 GSK group of companies. All rights reserved.

December 2023 | NX-GB-GVU-WCNT-230008 (V1.0)